SIP
NAGE

Stoneridge Investment Partners’s Niagen Bioscience NAGE Stock Holding History

Stoneridge Investment Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Sell
14,477
-36,164
-71% -$147K 0.03% 144
2026
Q1 		$223K Hold
50,641
– – 0.16% 94
2025
Q4 		$322K Buy
+50,641
New +$352K 0.22% 85

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Stoneridge Investment Partners's NAGE Position: Q2 2026 in Review

Stoneridge Investment Partners reduced its Niagen Bioscience (NAGE) stake by 71% in Q2 2026, selling an estimated $147K and leaving 14,477 shares worth $49K. The position accounts for 0.03% of the portfolio, ranked #144.

Stoneridge Investment Partners first reported a position in NAGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $322K in Q4 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Stoneridge Investment Partners held 14,477 shares of Niagen Bioscience worth $49K as of Q2 2026.
  • Stoneridge Investment Partners sold 36,164 Niagen Bioscience shares in Q2 2026, an estimated $147K.
  • Niagen Bioscience made up 0.03% of Stoneridge Investment Partners's portfolio in Q2 2026, its #144 holding.
  • Stoneridge Investment Partners first reported a position in Niagen Bioscience in Q4 2025 and has held it in 3 quarters since.
  • Stoneridge Investment Partners's Niagen Bioscience position peaked at $322K in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.